P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY

Autor: Ellen Ritchie, Tara L. Lin, Laura F. Newell, Robert K. Stuart, Scott Solomon, Richard Stone, Gary Schiller, Matthew Wieduwilt, Eileen Amy Ryan, Nalina Dronamraju, Jeffrey Lancet, Jorge Cortes

Publikováno v: HemaSphere, Vol 7, p e7753968 (2023)

Externí odkaz: https://doaj.org/article/adfffa9e836c4f858b031d7da2a6b267

Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients (Pts) with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Pooled Analysis of Defifrance and EBMT PASS Registries

Autor: Mohamad Mohty, Didier Blaise, Régis Peffault de Latour, Myriam Labopin, Hélène Labussière-Wallet, Vian Amber, Virginie Gandemer, Deborah Gutierrez, Nalina Dronamraju, Jean-Hugues Dalle, Ibrahim Yakoub-Agha

Publikováno v: Transplantation and Cellular Therapy. 29:S140-S141

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad81f7a25d9acae68d3705c36ff8134c
https://doi.org/10.1016/s2666-6367(23)00244-0

Outcomes of Defibrotide-Treated Patients with Anicteric/Icteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Results from the Defifrance Registry Study

Autor: Virginie Gandemer, Sarah Guenounou, Faezeh Legrand, Didier Blaise, Régis Peffault de Latour, François Duchêne, Nalina Dronamraju, Ibrahim Yakoub-Agha, Myriam Labopin, Jean-Hugues Dalle, Mohamad Mohty

Publikováno v: Blood. 140:12838-12839

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6d939b8711376debb5b90b593f3402fe
https://doi.org/10.1182/blood-2022-162755

Efficacy and safety of dual add‐on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52‐week, randomized, active‐controlled trial

Autor: Juan P. Frias, Donald C. Simonson, Marcia A. Testa, Guillermo Gonzalez‐Galvez, Anne L. Peters, Jill Maaske, Nalina Dronamraju, Eva Johnsson, Ricardo Garcia-Sanchez

Publikováno v: Diabetes, Obesity & Metabolism

Aims To evaluate the efficacy and safety of dapagliflozin (DAPA) + saxagliptin (SAXA) compared with glimepiride (GLIM) in patients with type 2 diabetes who were inadequately controlled [glycated haemoglobin (HbA1c) 7.5–10.5% (58–91 mmol/mol)] on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1c8d251ecf34e827947425950374c32
https://doi.org/10.1111/dom.13997

Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial

Autor: Tina Vilsbøll, Nalina Dronamraju, Ricardo García-Sánchez, Serge Jabbour, Ella Ekholm, Eva Johnsson, Marcus Lind

Publikováno v: Vilsbøll, T, Ekholm, E, Johnsson, E, Garcia-Sanchez, R, Dronamraju, N, Jabbour, S A & Lind, M 2020, ' Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes : A randomized, parallel-design, open-label, Phase 3 trial ', Diabetes, Obesity and Metabolism, vol. 22, no. 6, pp. 957-968 . https://doi.org/10.1111/dom.13981
Diabetes, Obesity & Metabolism

Aim: Efficacy and safety of dapagliflozin plus saxagliptin (DAPA + SAXA) were compared with insulin glargine (INS) in patients with type 2 diabetes (T2D) in a 52-week extension study. Materials and methods: This international Phase 3 study randomized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::488029793fdc1cbd6eeaf77da388e360
https://doi.org/10.1111/dom.13981